Jefferies downgrades Summit Therapeutics stock rating on trial risks
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump sees ’very bad’ future for NATO if allies do not help in Iran- FT interview Oil spike may trim global GDP by 0.3%, push inflation higher: Goldman Asia shares cautious, oil gains on Hormuz doubts US Economy: $100 oil triggers a dual-edged sword for domestic growth 🧠 Upgrade to AI Insights (South Africa Philippines Nigeria) 🧠 Upgrade to AI Insights Jefferies downgrades Summit Therapeutics stock rating on trial risks By Analyst Ratings Published 03/16/2026, 01:37 AM Jefferies downgrades Summit Therapeutics stock rating on trial risks 0 SMMT 4.27% Investing.com - Jefferies downgraded Summit Therapeutics plc (NASDAQ:SMMT) to Hold from Buy and cut its price target to $15 from $42. The stock currently trades at $16.12, slightly above the new target. According to InvestingPro data, analysts do not anticipate the company will be profitable this year, with the stock down 22% over the past year. Analyst Faisal Khurshid cited risks associated with four major catalysts expected in 2026 for the company. The firm’s base case for the HARMONi-6 trial is interim overall survival of approximately 0.8 and not statistically significant. Jefferies said the HARMONi-3 progression-free survival may be acceptable, but a clear win is uncertain given the translation from China to global markets. For deeper insights into SMMT’s financial health and comprehensive analysis, investors can access the company’s Pro Research Report, available for this and 1,400+ other US equities. The HARMONi-2 final overall survival should not add much value, according to the firm. The biologics license application filed in EGFR-mutant non-small cell lung cancer against FDA wishes appears to face challenges. "Net-net, PD-1/VEGF is a promising class and SMMT was the early mover, but we’d look for another way to play," Khurshid wrote. In other recent news, Summit Therapeutics reported a significant earnings per share miss for the fourth quarter of 2025....
Read full article at source